Category: Press Releases

Iconic, Sport-Inspired Brand Celebrates Summer with Vibrant Prints and Neon Accents

Sun, sand, and saltwater along the shores of trendy Miami Beach create the perfect backdrop for U.S. Polo Assn.’s Summer 2022 Collection. This season’s global photo shoot showcases beachside models lounging beside breezy palms and vibrant lifeguard towers, wearing pops of neon and bold tropical prints. The collection also brings colorful polo shirts, shorts, and graphic t-shirts alongside swimwear and essential summer accessories, including bucket hats and trendy handbags.

Consumers in-store and online around the world can look for color blocked brights and timeless resort stripes inspired by the sunlit Miami horizon. U.S. Polo Assn. has given summer style a refresh with an emphasis on breathable, lightweight fabrics to make fun in the sun easy and breezy. Fans of the brand can bask in soft knit tank dresses and preppy cotton shirts to make the most of a sun-kissed summer with U.S. Polo Assn.

“The inspiration for our Summer 2022 Collection comes from the bold color palette of the sunset and sea. Rich colors bring rejuvenating energy to our classic style that’s in step with today’s current trends,” says Brian Kaminer, SVP of Brand and Product Development for the U.S. Polo Assn. brand. “Innovating new fabrics with textural details make our timeless trends fresh for customers to approach the summer in style.”

U.S. Polo Assn. is known for its sport-inspired, classic American style. The brand’s signature red, white, and blue stripe is used in a variety of ways to add an element of surprise to each garment. Each U.S. Polo Assn. collection takes classic designs to a new level with unique styling, high-quality fabrics, and seasonal comfort. The Summer 2022 Collection follows suit with bold and fresh assortments that offer a wide array of options, including USPA Life apparel with sustainable aspects.

“These are exciting times for the U.S. Polo Assn. brand, with new stores opening around the world, and now the launch of our amazing Summer 2022 Collection,” says J. Michael Prince, President and CEO of USPA Global Licensing, which manages the global, multi-billion-dollar U.S. Polo Assn. brand. “Every season the U.S. Polo Assn. Team works to share our authentic connection to the sport of polo with our customers anywhere, anytime they want to shop, while offering an authentic and service-oriented experience.”

About U.S. Polo Assn. and USPA Global Licensing Inc. (USPAGL)

U.S. Polo Assn. is the official brand of the United States Polo Association (USPA), the nonprofit governing body for the sport of polo in the United States and one of the oldest sports governing bodies, having been founded in 1890. With a multi-billion-dollar global footprint and worldwide distribution through some 1,200 U.S. Polo Assn. retail stores, department stores, sporting goods channels, independent retailers and e-commerce, U.S. Polo Assn. offers apparel for men, women, and children, as well as accessories and footwear in 190 countries worldwide. Ranked the fifth largest sports licensor in License Global magazine’s 2020 list of “Top 150 Global Licensors,” U.S. Polo Assn. is named alongside such iconic sports brands as the National Football League, the National Basketball Association and Major League Baseball. Visit uspoloassnglobal.com.

USPA Global Licensing Inc. (USPAGL) is the for-profit subsidiary of the USPA and its exclusive worldwide licensor. USPAGL manages the global, multi-billion-dollar U.S. Polo Assn. brand and is the steward of the USPA’s intellectual properties, providing the sport with a long-term source of revenue. Through its subsidiary, Global Polo Entertainment (GPE), USPAGL also manages Global Polo TV, the world’s leading digital platform with polo and lifestyle content. In addition, USPAGL partners with ESPN and beIN Sports globally to share the sport of polo broadcasts on television and on-demand to millions of viewers around the world. For more polo content visit globalpolo.com.

Press Release Contact: 

Stacey Kovalsky – Senior Director, Global Communications
Phone +001.561.790.8036 – Email: skovalsky@uspagl.com

Kaela Drake – PR & Communications
CoordinatorPhone +001.561.461.8596 – Email: kdrake@uspagl.com

Related Images

Image 1: U.S. Polo Assn.

U.S. Polo Assn.

This content was issued through the press release distribution service at Newswire.com.

Attachment

• U.S. Polo Assn.

LONDON and NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) — Pharma Intelligence, a leading provider of specialist intelligence, data, and software for clinical trials, drug development, and regulatory compliance, announces that Warburg Pincus, a leading global growth investor, has completed its acquisition of the business from Informa PLC (LSE:INF.L), the international Academic Markets, B2B Markets and Digital Services Group. The acquisition includes Informa’s full portfolio of specialist brands which includes the Citeline suite of products (Trialtrove, Sitetrove, Pharmaprojects) as well as Biomedtracker, Clinerion, Datamonitor Healthcare, Pink Sheet, Scrip, Skipta, and TrialScope.

Pharma Intelligence will now enter its next phase of growth under new ownership. As announced on February 10, Mubadala Investment Company, the Abu Dhabi based investment company, joins Warburg Pincus in the investment. Informa retains a 15% equity interest in the business.

The investors plan to extend the company’s leading position in the $22 billion pharmaceutical data and analytics market by increasing focus and investment in innovation and product development to improve efficiency in the drug development life cycle.

The company holds the leading position in the clinical trial intelligence space, providing insights on patient enrollment and demographics, trial progress, individual trial sites and investigators for more than 375,000 clinical trials across 180 countries. The company’s solutions are used by 3,000 pharmaceutical companies and CROs in their clinical trial design, commercial strategy, and regulatory compliance processes to maximize the likelihood of success of introducing products to market.

Appointment of Executive Chair
Pharma Intelligence is also delighted to announce the appointment of Jay Nadler as Executive Chair, effective immediately. Jay has led and advised leading companies providing data and analytics, software, and technology-enabled services to a number of industry sectors including life sciences for more than 30 years. He is the current Executive Chair of Sagent Lending Technologies, former CEO of Clarivate, former COO of Interactive Data Corporation, and the former President of Information Holdings’ Pharma Business. He has worked closely with Warburg Pincus for more than 20 years as a portfolio company executive, advisor, and Board member, and has also been an advisor to the firm.

Jay Nadler, Executive Chair, Pharma Intelligence, said, “I am honored to join the Board of Pharma Intelligence and look forward to partnering with Ramsey Hashem, the rest of the management team, employees, and customers, as we work together to introduce more efficiency into the drug development lifecycle. As an independent company, with additional focus and investment, Pharma Intelligence will deliver additional value to all industry stakeholders. I am particularly excited about introducing innovative products to the market, such as Citeline Predict, that leverage the company’s unique data sets, deep understanding of customer challenges, and the latest advancements in data science.”

Ramsey Hashem, CEO, Pharma Intelligence, said, “As we join the Warburg Pincus group of companies, our commitment and vision for the future remain steadfast. With Jay Nadler on board as Executive Chair, we will be able to accelerate growth and take advantage of market opportunities and investments like never before. We look forward to working closely with the team at Warburg Pincus and continuing to deliver our world class suite of products and services to our customers that rely on our insights to make strategic business decisions every day.”

Adarsh Sarma, co-head of Europe at Warburg Pincus and Chandler Reedy, Head of Strategic Investments at Warburg Pincus said, “We are delighted that the acquisition is complete, and we can focus our efforts entirely on the next phase of growth. Working closely with Jay Nadler and the management team, we will build on the excellent work already undertaken and use our industry expertise and experience successfully scaling pharma, health tech and B2B information services businesses, to help the company achieve its growth potential.”

David Reis and Amr Kronfol, Managing Directors at Warburg Pincus, said, “This is an exciting time for the business, its employees, and customers, as Pharma Intelligence becomes an independent company able to achieve its full growth potential. We believe Pharma Intelligence is a high-quality, fast-growing company and that with its outstanding people, products and services and our investment, it will play an increasingly important role within the global pharma and healthcare industry.”

About Pharma Intelligence
Pharma Intelligence powers a full suite of analysis products – Datamonitor Healthcare™, Sitetrove™, Trialtrove™, Pharmaprojects™, Biomedtracker™, Scrip™, Pink Sheet™ and In Vivo™ – to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.

With more than 400 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information, visit pharmaintelligence.informa.com.

About Warburg Pincus
Warburg Pincus LLC is a leading global growth investor. The firm has more than $80 billion in assets under management. The firm’s active portfolio of more than 245 companies is highly diversified by stage, sector, and geography. Warburg Pincus is an experienced partner to management teams seeking to build durable companies with sustainable value. Founded in 1966, Warburg Pincus has raised 21 private equity and 2 real estate funds, which have invested more than $103 billion in over 1,025 companies in more than 40 countries. The firm is headquartered in New York with offices in Amsterdam, Beijing, Berlin, Hong Kong, Houston, London, Luxembourg, Mumbai, Mauritius, San Francisco, São Paulo, Shanghai, and Singapore. For more information, please visit www.warburgpincus.com. Follow us on LinkedIn.

About Mubadala Investment Company
Mubadala Investment Company is a sovereign investor managing a global portfolio, aimed at generating sustainable financial returns for the Government of Abu Dhabi.

Mubadala’s $284 billion portfolio spans six continents with interests in multiple sectors and asset classes. It leverages its deep sectoral expertise and long-standing partnerships to drive sustainable growth and profit, while supporting the continued diversification and global integration of the economy of the United Arab Emirates.

For more information about Mubadala Investment Company, please visit: www.mubadala.com

Media Contacts
Pharma Intelligence
Blair Dawson | Vice President, Commercial Development & Launch
919-413-4616 / blair.dawson@informa.com

Warburg Pincus
Jenna Ward | Europe Communications Director
+44 7570844338 / jenna.ward@warburgpincus.com

Stratipath, a global leader in AI-based precision diagnostic solutions, today announced that its AI software for prognostic risk stratification of breast cancers, Stratipath Breast, is now CE-IVD marked.

Stockholm, Sweden, June 01, 2022 (GLOBE NEWSWIRE) — Stratipath, a global leader in AI-based precision diagnostic solutions, today announced that its AI software for prognostic risk stratification of breast cancers, Stratipath Breast, is now CE-IVD marked. This paves the way for clinical implementation in the European Union. Based on the analysis of digital histopathology whole slide images, stained with haematoxylin and eosin (H&E) the software provides novel decision support to clinicians and enables precision medicine for more patients.

Stratipath Breast is the first EU regulatory compliant solution for risk stratification of breast cancer using AI-based precision diagnostics to analyse cancer tissue, and enabling identification of patients with increased risk of disease progression.

In contrast to traditional molecular tests, AI-based risk stratification enables faster turnaround times for results, provides new information at the point of diagnosis and reduces the need for expensive molecular testing, allowing for wider use and benefit to more patients.

“Stratipath Breast offers a faster and cheaper alternative to molecular assays, allowing more patients to have access to precision diagnostics. By using Stratipath Breast, clinicians can diagnose with support from prognostic information, while reducing laboratory time and costs,” says Johan Hartman, professor in pathology at Karolinska Institutet, Stockholm, and co-founder of Stratipath.

Histological tumour grade is a strong prognostic indicator of breast cancer. Grading of invasive breast cancer is performed on all invasive breast cancers based on morphological assessment, according to the Nottingham Histologic Grade (NHG), resulting in the low- to high-risk categories NHG 1, 2 or 3. But currently, more than 50% of all breast cancer patients are categorised as of intermediate risk (i.e NHG 2), which provides little clinical utility for treatment decision-making. The consequential over- and undertreatment of patients with early breast cancer has become one of the main challenges for treating physicians, and the clinical decisions are often dependent on expensive molecular assays that are not accessible to the majority of patients.

Using deep learning, Stratipath Breast enables cancer detection and classification of intermediate risk tumours into low- and high-risk groups, based on grade-related tumour morphology. The stratification comes from a rigorous scientific development process and validation using multi-source real-world datasets, comprising histopathology images and associated clinical outcome data.

The system measures risk-associated morphological patterns locally in the image and aggregates this information across the analysed tissue area to establish whether the tumour belongs to the high- or low-risk group. Results from Stratipath Breast provide prognostic information and are intended to be used as a decision support tool, together with other clinical and pathological information.

Stratipath Breast provides an optimal workflow through integration with leading digital pathology solutions. It can also be used on its own, via the Stratipath customer web portal. Access to Stratipath Breast will be provided as a Software as a Service solution, by a subscription or pay as you use model. Not marketed in the USA.

About Stratipath
Stratipath is a spin-out from Karolinska Institutet in Stockholm, Sweden, bringing pioneering research in AI and precision medicine into clinical use. The company was founded in 2019 by Johan Hartman, M.D., PhD, Mattias Rantalainen, PhD and Fredrik Wetterhall with a mission to radically improve cancer treatment decisions and patient outcomes. Stratipath offers an AI precision diagnostic solution for healthcare and can offer an accelerated path for pharma and biotech companies to identify patients most likely to benefit from novel therapies.

Attachments

• Deep learning analysis of digital histopathology whole slide images
• First CE-IVD marked AI solution for prognostic risk stratification of breast cancer patients.

Lars Lengquist
Stratipath
+46 709574782
lars.lengquist.press@stratipath.com

 

LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) — Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™ and AI Predictive Biomarkers™, announced today that its EyeArt® system has been confirmed to have “sufficient high quality evidence” as “safe and cost-effective,” and is the only diabetic eye screening AI technology ready for live clinical implementation in the United Kingdom, according to the report, “Automated grading in the Diabetic Eye Screening Programme- External review against programme appraisal criteria for the UK National Screening Committee.”

The comprehensive review of 10 AI algorithms’ performance, reported in peer-reviewed publications, was conducted for the UK National Screening Committee (NSC), which provides advice about all aspects of population screening to the National Health Service (NHS) and the ministers of the four UK countries (England, Scotland, Wales, and Northern Ireland).

The 169-page NSC report identified the EyeArt v2.1 algorithm for autonomous diabetic retinopathy screening as the only AI technology ready for live clinical implementation in the UK. Study authors concluded that “there is sufficient high-quality evidence from the EDESP (English Diabetic Eye Screening Program) that EyeArt v2.1 may be safe and cost-effective either using it for level 1 grading or as a filter prior to manual grading.”

The EyeArt system is now being planned for live clinical use within the North East London NHS Diabetes Eye Screening Programme as part of a project led by the Moorfields Eye Hospital NHS Foundation Trust and supported jointly by the NHSX AI Lab and the UK Health Foundation. The funded program will implement the live clinical use of artificial intelligence and assess its effectiveness in addressing racial and ethical health inequalities, and its acceptability by healthcare providers and people with diabetes.

“We are gratified by the NSC’s confirmation that the EyeArt system stands out from other solutions for its safety and cost-effectiveness and would like to thank our clinical collaborators within various diabetes eye screening programs (DESP) throughout the National Health Service,” said Kaushal Solanki, PhD, founder and CEO of Eyenuk. “We look forward to working with the Moorfields Eye Hospital and the North East London NHS DESP to deploy the EyeArt system for live clinical use.”

The UK has been leading the world in diabetic retinopathy screening, achieving patient uptake rates of over 80% (screening nearly 2.5 million diabetes patients annually). In most countries, fewer than half of diabetes patients receive annual eye screening. Thanks to the UK’s comprehensive screening program, it is the only country where diabetic retinopathy is no longer the leading cause of blindness in the working-age adults.

Eyenuk will showcase the EyeArt AI System during the American Diabetes Association’s 82nd Scientific Sessions in New Orleans, June 3-7. Attendees can visit booth #1709 to learn how the EyeArt system can help their organizations improve diabetes management and population health.

About Eyenuk, Inc.
Eyenuk, Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening™ for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk, and Alzheimer’s disease. Find Eyenuk online on its website, Twitter, Facebook, and LinkedIn.

About the EyeArt AI System
The EyeArt AI System provides fully autonomous diabetic retinopathy (DR) screening, including retinal imaging, DR detection based on international clinical standards and immediate reporting, in a single office visit during a diabetic patient’s regular exam. Once the patient’s fundus images have been captured and submitted to the EyeArt AI System, the DR detection results are available in a PDF report in less than 30 seconds.

The EyeArt AI System was developed with funding from the U.S. National Institutes of Health (NIH) and is validated by the U.K. National Health Service (NHS). In addition to U.S. Food and Drug Administration (FDA) 510(k) clearance, the EyeArt AI System has CE marking as a class 2a medical device in the European Union and a Health Canada license. It is the most extensively validated AI technology for autonomous DR detection, tested on over 500,000 patients globally with 2 million images collected in clinical environments. It is designed to be General Data Protection Regulation (GDPR) and Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant. The EyeArt AI System is reimbursable by government and private payors in the U.S. under the newly created Category 1 Current Procedural Terminology (CPT) code 92229.

VIDEO: Learn more about the EyeArt AI System for Autonomous Detection of Diabetic Retinopathy

Media Contact
Todd Stein
+1 510 417 0612
todd@toddsteincommunications.com

Eyenuk, Inc. Contact
Frank Cheng, President & CCO
+1 818 835 3585
frank.cheng@eyenuk.com

WAYNE, Pa., June 01, 2022 (GLOBE NEWSWIRE) — Veranova, formerly known as Johnson Matthey Health, has launched as an independent company following the acquisition by Altaris Capital Partners, LLC from Johnson Matthey PLC (LSE: JMAT).

Veranova is a leading global contract development and manufacturing organization (CDMO) focused on specialty Active Pharmaceutical Ingredients (APIs). With approximately 900 employees, Veranova serves the pharmaceutical industry with a full spectrum of API and drug development services, from process design through to commercial manufacturing.

Veranova is headquartered in Wayne, PA, with cGMP manufacturing operations in West Deptford, NJ; Devens, MA; North Andover, MA; Annan, UK; and Edinburgh, UK, and manufacturing and R&D centers in Cambridge, UK; and Yantai, China.

Veranova and its predecessor entities have a strong legacy of innovation in the pharmaceutical industry which spans more than a century and the development of more than 100 APIs, including the first platinum-based drugs for cancer treatment.

Today, Veranova is a leader in the development and manufacture of complex and highly potent APIs, with expertise across a diverse range of chemistry processes and technologies, including drug linkers for antibody drug conjugates. Veranova holds over 425 active patents and works with a wide variety of pharmaceutical corporations and biotechnology companies.

Originating from the Latin words ‘vērus‘ meaning ‘true’ and ‘nŏvus‘ meaning ‘new’, the Veranova name represents the reliability and innovative approach the company seeks to deliver to its customers.

About Veranova

Veranova is a global leader in process development and manufacturing of APIs, with a focus on specialty and complex products. Veranova is headquartered in Wayne, PA, and has operations in North America, Europe and Asia.  For more information, please visit www.veranova.com.

About Altaris Capital Partners

Altaris is a healthcare investment firm with an exclusive focus on building companies that deliver value to the healthcare system through innovation and efficiency. Since its inception in 2003, Altaris has invested in more than 45 healthcare companies which have generated significant value appreciation for investors. Altaris is headquartered in New York City and manages more than $5.0 billion of equity capital. For more information, please visit www.altariscap.com.

Contact Details

For further information and interview opportunities with Veranova, please contact:

Media Inquiries

Charles Ben-Cofie

Senior Content Manager, Notch Communications

T +44 (0) 161 457 7230

E charles.ben-cofie@notchcommunications.co.uk

Related Images

Image 1: Veranova, formerly Johnson Matthey Health

Veranova, formerly Johnson Matthey Health, has launched as an independent company following the acquisition by Altaris Capital Partners, LLC

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Veranova, formerly Johnson Matthey Health